Search JIM Advanced Search

Journal of Integrative Medicine ›› 2024, Vol. 22 ›› Issue (5): 545-551.doi: 10.1016/j.joim.2024.07.002 Get rights and content

• Original Clinical Research • Previous Articles     Next Articles

Efficacy and safety of Tianqi Pingchan Granule, a compound Chinese herbal medicine, for levodopa-induced dyskinesia in Parkinson’s disease: A randomized double-blind placebo-controlled trial

Yu Zhang a 1, Xiao-bo Zhu a 1, Yang Zhao b, Gui-yun Cui c, Wen-tao Li d, Can-xing Yuan e, Jian-ping Huang f, Ying Wan a, Na Wu a, Lu Song a, Jia-hao Zhao a, Yan Liang b, Chuan-ying Xu c, Mei-juan Liu d, Chen Gao e, Xin-xin Chen f, Zhen-guo Liu a   

  1. a. Department of Neurology, Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
    b. Department of Neurology, Nanjing Hospital of Chinese Medicine Affiliated to Nanjing University of Chinese Medicine, Nanjing 210022, Jiangsu Province, China
    c. Parkinson’s Disease Center, the Affiliated Hospital of Xuzhou Medical University, Xuzhou 221004, Jiangsu Province, China
    d. Department of Neurology, Shanghai Municipal Hospital of Traditional Chinese Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai 200071, China
    e. Department of Neurology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China
    f. Department of Neurology, Wenzhou Central Hospital, Wenzhou 325000, Zhejiang Province, China
  • Received:2023-07-07 Accepted:2024-04-15 Online:2024-09-16 Published:2024-09-27
  • Contact: Zhen-guo Liu E-mail:liuzhenguo@xinhuamed.com.cn

Background
Patients with Parkinson’s disease (PD) undergoing long-term levodopa therapy are prone to develop levodopa-induced dyskinesia (LID). Amantadine is the main drug recommended for the treatment of LID by current guidelines, but it is far from meeting clinical needs. Tianqi Pingchan Granule (TPG), a compound Chinese herbal medicine, has been developed to relieve symptom of LID.
Objective
This randomized controlled trial evaluated the efficacy and safety of the combination of TPG and amantadine for LID.
Design, setting, participants and interventions
This is a randomized double-blind placebo-controlled trial, conducted from January 2020 to August 2021 at 6 sites in Jiangsu, Zhejiang and Shanghai, China. One hundred PD patients with ≥ 0.5 h of LID were randomly assigned to either the TPG plus amantadine group (TPG group) or the placebo plus amantadine group (placebo group), and treated for a period of 12 weeks. To ensure unbiased results, all study participants, investigators and sponsors were unaware of group allocations. Additionally, the data analysts remained blinded until the analysis was finalized.
Main outcome measures
The primary outcome was assessed using the Unified Dyskinesia Rating Scale (UDysRS) (Range 0–104). The key secondary end point was improvement of motor and non-motor symptoms. Safety analyses included all enrolled patients.
Results
One hundred patients were enrolled and randomized into the two treatment groups. The changes in UDysRS at week 12 were –11.02 for the TPG group and –4.19 for the placebo group (treatment difference –6.83 [–10.53 to –3.12]; P = 0.0004). Adverse events were reported for 2 of 50 patients (4.0%) in each of the groups.
Conclusion
This study indicated that a 12-week treatment of amantadine plus TPG effectively reduced UDysRS scores and was well tolerated, demonstrating the efficacy and safety of TPG for the treatment of LID in PD.
Trial registration: 
ClinicalTrials.gov
 identifier: NCT04173832.

Key words: Parkinson’s disease, Tianqi Pingchan Granule, Levodopa-induced dyskinesia

[1] Si-chun Gu, Jie Zhou, Qing Ye, Can-xing Yuan. Pingchan granule for depressive symptoms in Parkinson’s disease: A randomized, double-blind, placebo-controlled trial. Journal of Integrative Medicine, 2021, 19(2): 120-128.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
[1] Ru-jiang Li, Shu-dong Qiu, Hong-xia Chen, Li-rong Wang. Immunomodulatory effects of Astragalus polysaccharide in diabetic mice. Journal of Chinese Integrative Medicine, 2008, 6(2): 166-170
[2] Li Ji. Research advances in the relationship between prolactin and spontaneous abortion. Journal of Chinese Integrative Medicine, 2012, 10(1): 7-12
[3] Désirée Lötzke, Peter Heusser, Arndt Büssing. A systematic literature review on the effectiveness of eurythmy therapy. Journal of Integrative Medicine, 2015, 13(4): 217-230
[4] Lie-ming Xu, Yi-yang Hu. Studies on treatment of fatty liver with traditional Chinese medicine. Journal of Chinese Integrative Medicine, 2003, 1(2): 138-141
[5] Cai Lin-lin, Li Hao, Liu Jian-gang, Liu Long-tao, Guan Jie, Liu Ming-fang, Hu Jia, Wei Yun. Effects of early intervention with Huannao Yicong formula effective components on behavior and cholinergic system of β-amyloid precursor protein transgenic mice. Journal of Chinese Integrative Medicine, 2011, 9(3): 292-298
[6] Ya-lei Liu, Zhen-yu Zhou, Min Gao, Guang Ji, Cheng Huang, Sheng-jie Fan. Therapeutic effects of herbal formula Huangqisan on metabolic disorders via SREBF1, SCD1 and AMPK signaling pathway. Journal of Integrative Medicine, 2021, 19(2): 167-176
[7] Reem Abdul-Latif, Ieva Stupans, Ayman Allahham, Benu Adhikari, Thilini Thrimawithana. Natural antioxidants in the management of Parkinson’s disease: review of evidence from cell line and animal models. Journal of Integrative Medicine, 2021, 19(4): 300-310